SCCA Clinical Trial Openings

clinical-trialsListed below are clinical trials that have opened at SCCA in the last several weeks. These trials are looking at new treatments for patients with multiple myeloma, myelofibrosis , non-small cell lung cancer, and squamous cell carcinoma of the head and neck, lung, or esophagus. For more information about these trials, click on the links below. Check out our website to learn about the more than 200 ongoing clinical trials at SCCA. And follow us on Twitter at @SCCA_Trials for information about recently opened trials.

Carfilzomib + Melphalan/Prednisone for Newly Diagnosed Multiple Myeloma (CLARION Study)
A Randomized, Open-Label Phase 3 Study of Carfilzomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma

JAK-2 Inhibitor Prior to Transplant for Myelofibrosis (9033)
JAK-2 Inhibitor Prior to Allogeneic Stem Cell Transplant for Patients with Primary and Secondary Myelofibrosis: A Prospective Study

CO-1686 for Non-Small Cell Lung Cancer (UW14031)
A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients With Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)

Selinexor Treatment of Advanced Relapsed/Refractory Squamous Cell Carcinomas (14032)
A Phase 2, Open-Label Study of the Safety and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck, Lung, or Esophagus (STARRS)

    Posted in Uncategorized | Leave a comment

    Five Minutes With Dr. Jonathan Wright

    Editor’s Note: “Five Minutes With” is a new series about SCCA’s staff and physicians that is designed to give our readers a look into the “non-clinical” side of the people who work at SCCA. If there’s a doctor or staff member who you would like to know more about, or perhaps a question that you would like us to ask, please let us know.

    jonathan-wright-225Jonathan Wright specializes in the treatment of bladder and prostate cancer. He’s been treating patients here at SCCA for the last seven years. A Washington native and devout Husky fan, Wright was raised in Yakima. He attended Boston College and graduated with a degree in economics–he was also captain of the varsity tennis team in his senior year there. Dr. Wright received his medical degree at the University of Washington. He’s married, has three children, and lives on the Eastside. Dr. Wright is also the leader of MoDAWGs, a team that comes together every November in support of Movember. Learn more about Dr. Wright’s clinical and research expertise here.

    What’s the last book you read?
    The Man in the Iron Mask

    What hobbies or activities do you enjoy doing outside of work?
    Playing tennis and golf. I love to eat, so I have to exercise to keep my weight down, so I run a lot. It’s an easy way in a short amount of time to get some exercise and get back to my family.

    prince-racketHead, Wilson or Prince?

    Do you have a personal motto?
    “Live with Intention.” It was my mother’s motto as she fought cancer for 10 years. She did it to the fullest and I have a responsibility to continue it for her.

    Who is the person you most admire?
    My father. He was an Army infantryman from the Vietnam war who returned and went to law school and became a tax attorney. He taught me everything I know about hard work, love of family, and personal responsibility.

    What is your favorite place to go in Seattle?
    Safeco Field.

    What is your favorite restaurant?
    I’m very partial to the Metropolitan Grill. I know it’s important to limit the amount of red meat we have, but I love a good steak, a Caesar salad and a glass of red wine. We also like Jak’s Grill.

    husky-WMariners, Sounders, or Seahawks?
    I’m a huge fan of all three as a native of Washington state. Can’t leave Husky Football off that list, I grew up writing letters to Don James.

    What career could you see yourself in if you weren’t an oncologist?
    Within medicine, it would be a family doctor. Outside of medicine, I could have been an economist.

    Why Movember?
    You say why, I say why not! It’s a no-brainer. It’s a cause about raising awareness about men’s health and subsequently helping advance research for prostate and testicular cancer. We all know that men hate to go the doctor–I hate to go to the doctor, and young men don’t want to go to the doctor. And yet we all need to go and get regular checkups for preventive care. Prostate cancer is the number one cancer diagnosed in men. It’s the number two killer of men. Testicular cancer is the number one solid tumor in men under the age of 35. If those are not enough reasons to get behind a campaign that supports men’s health, I don’t know what is.

      Posted in Five Minutes With | Leave a comment

      Fridays with Dr. Gralow

      Editor’s Note: Dr. Julie Gralow is the director of Breast Medical Oncology at SCCA. In celebration of Breast Cancer Awareness Month, we’ve asked Dr. Gralow to answer readers’ questions about breast cancer every Friday during October. 

      In this final installment of Fridays with Dr. Gralow, Dr. Gralow addresses the question, “How does my family history of breast cancer impact my chances of developing breast cancer, and does my father’s side of the family count?” In the video below, Dr. Gralow discusses how heredity factors into your chance of developing breast cancer.

        Posted in Uncategorized | Leave a comment

        Better Understanding Lymphoma

        It used to be that lymphoma specialists believed that how a patient responded to a particular treatment was almost entirely dependent on the lymphoma itself–what kind of mutations it had, what its growth rate was, and so on. These days, however, researchers have come to realize that the “microenvironment” surrounding lymphoma is almost as important to a patient’s outcome as the lymphoma itself. In this interview with Patient Power’s Andrew Schorr, Dr. Oliver Press  describes the various components of this microenvironment and how manipulating it might help to more effectively kill lymphoma cells.

          Posted in Uncategorized | Leave a comment

          SCCA Clinical Trial Openings

          stemcellsListed below are clinical trials that have opened at SCCA in the last several weeks. These trials are looking at new treatments for patients with prostate cancer, metastatic Merkel cell carcinoma, advanced solid tumors, and recurrent thoracic cancers. For more information about these trials, click on the links below. Check out our website to learn about the more than 200 ongoing clinical trials at SCCA. And follow us on Twitter at @SCCA_Trials for information about recently opened trials.

          Seizure Risk Evaluation of Patients Treated with Enzalutamide
          A Multicenter, Single-Arm, Open-Label, Post-Marketing Safety Study to Evaluate the Risk of Seizure Among Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Enzalutamide Who Are at Potential Increased Risk of Seizure

          MSB0010718C for Metastatic Merkel Cell Carcinoma
          A Phase II, Open-Label, Multicenter Trial to Investigate the Clinical Activity and Safety of MSB0010718C in Subjects With Merkel Cell Carcinoma

          ME-344 in Combination With Hycamtin® for Solid Tumors
          A Phase Ib Open-Label Study of the Safety and Tolerability of ME-344 Given in Combination With Topotecan (Hycamtin®) in Patients With Solid Tumors

          PF-05082566 Plus MK-3475 for Advanced Solid Tumors
          A Phase I Study Of The 4-1BB Agonist PF-05082566 in Combination With The PD-1 Inhibitor MK-3475 in Patients With Advanced Solid Tumors

          Proton Beam Radiation Therapy for Recurrent Thoracic Cancer (9148)
          Definitive Re-Irradiation With Proton Beam Radiotherapy for Patients With Recurrent Thoracic Cancers

            Posted in Clinical Trials | Leave a comment
            • This-One-Thing-260